Combination Drug Therapy for Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center

Criteria

Inclusion Criteria:

• Histological diagnosis of GBM (WHO grade 4)

• Subjects ≥18 years of age

• Patients must have a life expectancy of >6 months

• Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)

• Patients must have a KPS rating of ≥70

• Patients should not have received any prior systemic anti-cancer therapy

• Patients must be negative for HIV, Hepatitis B and C

• Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:

• Hemoglobin (Hgb)> 8 g/dL

• Absolute Neutrophil Count (ANC) > 1,000/mm3

• Platelet count > 100,000/mm3

• Creatinine < 2 mg/dL

• Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 3x upper limit of normal (ULN)

Exclusion Criteria:

• Metastatic disease

• Diseases or conditions that obscure toxicity or dangerously alter drug metabolism

• Serious intercurrent medical illness

• Inadequately controlled hypertension

• History of myocardial infarction or unstable angina within 6 months

• History of stroke or transient ischemic attack within 6 months